Publication date: September 2026 Source: Prostate International, Volume 14, Issue 3 Author(s): Jong Hoo Lee, Hye Jin Oh, Hyo Jeong Koo, Mee Young Kim, Choung-Soo Kim, Bumjin Lim, Ji Youl Lee, Woong-Yang Park
A cfDNA-based DNA methylation classifier for distinguishing prostate cancer from benign prostatic hyperplasia. // Prostate International. – URL: https://www.sciencedirect.com/science/article/pii/S2287888226000073?dgcid=rss_sd_all
A cfDNA-based DNA methylation classifier for distinguishing prostate cancer from benign prostatic hyperplasia. Prostate International. https://www.sciencedirect.com/science/article/pii/S2287888226000073?dgcid=rss_sd_all
“A cfDNA-based DNA methylation classifier for distinguishing prostate cancer from benign prostatic hyperplasia.” Prostate International.
@article{article63299,
title = {A cfDNA-based DNA methylation classifier for distinguishing prostate cancer from benign prostatic hyperplasia},
journal = {Prostate International},
url = {https://www.sciencedirect.com/science/article/pii/S2287888226000073?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...